Screening
SAH is associated with high mortality and morbidity. Screening provides a major opportunity to treat intracranial aneurysms before catastrophic rupture. However, it is uncertain that widely applied screening programs are cost-effective given the low prevalence of cerebral aneurysms in the general population and risk of rupture. In addition, there are controversies about when and how to treat unruptured intracranial aneurysms. Patients who have two or more first-degree relatives with SAH or those with autosomal dominant polycystic kidney disease are potential candidates for aneurysm screening with computed tomography angiography (CTA) or magnetic resonance angiography (MRA).[25] In addition, patients who have survived SAH are at higher risk for another, due to a newly formed aneurysm. However, whether this subgroup will benefit from screening and how it should be performed is undecided.[29][72]
Use of this content is subject to our disclaimer